Prosecution Insights
Last updated: November 12, 2026
Application No. 18/839,192

METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE

Non-Final OA §102§103§112
Filed
Aug 16, 2024
Priority
Feb 18, 2022 — provisional 63/311,564 +2 more
Examiner
SHIM, DAVID M.
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Vuja De Sciences Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
61 granted / 101 resolved
At TC average
Strong +58% interview lift
Without
With
+57.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
42 currently pending
Career history
147
Total Applications
across all art units

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 75, 77, 80, 81, 83, 84, 104-108, 117, 119, 123 and 134-139 are pending in the application. Claims 75, 77, 80, 81, 83, 104-108, 117, 119, 123, 134, 135 and 139 are rejected. Claims 80 and 83 are objected to. Claims 84 and 136-138 are withdrawn. Restriction/Election of Species Applicant’s election without traverse of Group I, claims 75, 77, 80, 81, 83, 104-108, 117, 119, 123, 134, 135 and 139, in the reply filed on July 27, 2026 is acknowledged. Claims 84 and 136-138 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on July 27, 2026. Priority This application is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/US2023/013285, filed on February 17, 2023, which claims benefit of Provisional Application No. 63/438,166, filed on January 10, 2023, which claims benefit of Provisional Application No. 63/311,564, filed on February 18, 2022. Information Disclosure Statement The Information Disclosure Statement(s) (IDS) filed on November 13, 2024, May 11, 2026 and June 16, 2026 are in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the Examiner has considered the IDS documents and signed copies of the 1449 forms are attached. Claim Objections Claims 80 and 83 are objected to because of the following informalities: Claim 80 should be amended to recite, “...the microscopic metastatic tumor is one or more single cells, or one or more...” for sake of clarity. Claim 83 should be amended to replace “The methods” with “The method” for sake of clarity and consistency. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. § 112(b): (b) CONCLUSION — The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. § 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 75, 77, 80, 81, 83, 104-108, 117 and 134 are rejected under 35 U.S.C. § 112(b) or 35 U.S.C. § 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. § 112, the applicant), regards as the invention. Claim 75 recites the expression “two or more active pharmaceutical ingredients (APIs) selected from: (a) a mTOR inhibitor; and (b) a histone deacetylase (HDAC) inhibitor” and is rejected as indefinite. Considering that claim 75 recites a closed Markush group of alternatives consisting of a mTOR inhibitor and a HDAC inhibitor, it is unclear whether Applicant intended “two” APIs- when selected from this group- to require a combination of a mTOR inhibitor and a HDAC inhibitor. For instance, it is unclear whether a prior art reference teaching two mTOR inhibitors or two HDAC inhibitors with respect to the instantly claimed method would be encompassed by the instant invention. It is, therefore, suggested Applicant amend claim 75 to clearly indicate the required combination, if any, of APIs. For the purpose examination, “two or more active pharmaceutical ingredients” is being interpreted as requiring at least one mTOR inhibitor and at least one HDAC inhibitor. Dependent claims 77, 80, 81, 83, 104-108, 117 and 134 do not correct this issue of indefiniteness and are likewise rejected. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 75, 77, 80, 105 and 134 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Liang et al. (Cancer Letters, 2019, 454:108-119). Regarding instant claims 75, 77, 80 and 134, Liang et al. teach “that combined 4SC-202 (a novel selective class I HDAC inhibitor) and INK128 (a selective mTORC1/C2 inhibitor) treatment exhibited synergistic effects on inhibiting cell growth, sphere-forming ability, subcutaneous tumor formation and ALDH1+ cancer stem cells (CSCs) in OSCC [i.e., oral squamous cell carcinoma].” See e.g., page 108. Liang et al. further teach “that combined 4SC-202 and INK128 treatment synergistically suppresses tumor formation via inducing apoptotic cell death and inhibiting self-renewal of OSCC cells.” See e.g., page 110. Liang et al. further teach “that combined 4SC-202 and INK128 treatment effectively blocks growth of recurrent OSCC in vivo through inhibiting cell proliferation and CSCs.” See e.g., page 112. Liang et al. further teach “[m]ice with CAL33 subcutaneous xenogeneic tumor were treated with 4SC-202 (100 mg/kg), INK128(0.4 mg/kg) or combination daily by oral gavage for 17 days.” See e.g., page 112. Liang et al. also teach “that combined 4SC-202 and INK128 treatment reduced the [squamous cell carcinoma] lesion surface areas...and invasive tumor growth.” See e.g., page 111. Note “4SC-202” is also known as domatinostat. See paragraph [00146] of instant specification for definition of term “microscopic metastatic tumor” as recited, for instance, in instant claim 75. See paragraph [00172] of instant specification for definition of term “partial remission” as recited in instant claim 105. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. § 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. (1 of 2) Claims 81, 104 and 106-108 are rejected under 35 U.S.C. § 103 as being unpatentable over Liang et al. (Cancer Letters, 2019, 454:108-119) in view of Maurizi et al. (Oncogene, 2018, 37(33):4626–4632) and Odri et al. (Cancers, 2022, 4(2):360). Determining the scope and contents of the prior art (See MPEP § 2141.01) Liang et al. teach “that combined 4SC-202 (a novel selective class I HDAC inhibitor) and INK128 (a selective mTORC1/C2 inhibitor) treatment exhibited synergistic effects on inhibiting cell growth, sphere-forming ability, subcutaneous tumor formation and ALDH1+ cancer stem cells (CSCs) in OSCC [i.e., oral squamous cell carcinoma].” See e.g., page 108. Lian et al. further teach a “combination of 4SC-202 and INK128 treatment effectively inhibits cell growth and CSCs in OSCCs by repressing SOX2 translationally.” See e.g., page 114. Ascertainment of the differences between the prior art and the claims (See MPEP § 2141.02) Regarding instant claim 81, Liang et al. does not teach the instantly claimed cancer cells (e.g., osteosarcoma). Liang et al., however, does teach that “upregulated SOX2 was associated with advanced and metastatic tumors in OSCC patients and was responsible for the drug-resistance property of OSCC cells.” See e.g., the abstract. Liang et al. also teach that a “combination of 4SC-202 and INK128 treatment effectively inhibits cell growth and CSCs in OSCCs by repressing SOX2 translationally.” See e.g., page 114. With respect to the SOX2 stem cell transcription factor, Maurizi et al. teach that “Sox2 is required for osteosarcoma initiation or development in a mouse tumor model and Sox2... [is] essential for the survival and proliferation of osteosarcoma cells.” See e.g., page 4627. Maurizi et al. further teach that the “disruption of Sox2-initiated pathways could be an effective strategy for the treatment of osteosarcoma.” See e.g., page 4626. Regarding instant claims 104 and 106-108, Liang et al. does not teach the instantly recited limitations with respect to the instantly claimed subjects. Unlike the instant claims that are drawn towards subjects having, for instance, osteosarcoma metastases, the teachings of Liang et al. are primarily drawn towards treatment of oral squamous cell carcinoma with a combination of a HDAC inhibitor and a mTOR inhibitor. See e.g., page 108. However, as discussed above, Liang et al. teach that a “combination of 4SC-202 and INK128 treatment effectively inhibits cell growth and CSCs in OSCCs by repressing SOX2 translationally.” See e.g., page 114. With respect to the SOX2 stem cell transcription factor, Maurizi et al. teach that “Sox2 is required for osteosarcoma initiation or development in a mouse tumor model and Sox2... [is] essential for the survival and proliferation of osteosarcoma cells.” See e.g., page 4627. Maurizi et al. further teach that the “disruption of Sox2-initiated pathways could be an effective strategy for the treatment of osteosarcoma.” See e.g., page 4626. Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) Regarding instant claim 81, considering that (1) Liang et al. teach upregulated SOX2 expression in human tissue samples of OSCC (see e.g., page 112) and (2) Maurizi et al. provide a nexus between SOX2 expression and osteosarcoma cell initiation, survival and proliferation (see e.g., page 4627), it would have been obvious for a person of ordinary skill in the art to apply the mTOR inhibitor/HDAC inhibitor combination taught by Liang et al. with respect to osteosarcoma cells. Considering that Maurizi et al. teach “that drugs that interfere with the activity of ... [SOX2] would be very effective in targeting and killing the entire tumor cell population in osteosarcomas and perhaps other cancers” (see e.g., page 4631), a person of ordinary skill in the art would have been motivated to employ the instantly claimed method. Regarding instant claims 104 and 106-108, it would, therefore, have been obvious to a person of ordinary skill in the art to apply the HDAC inhibitor/mTOR inhibitor taught by Liang et al. with respect to other cancers besides OSCC( e.g., osteosarcomas) that are associated with SOX2 expression. For instance, Mauirizi et al. teach the effect of SOX2 expression in a mouse osteoblast lineage with “a very high incidence of osteosarcomas, which occur early and frequently metastasize to other tissues and organs.” See e.g., page 4627. Furthermore, with respect to the various subject diagnosis requirements recited in instant claims 104 and 106-108, it would be within the ability of a skilled artisan to treat a subject at different stages of metastases- with or without implementing surgical resection- upon considering various factors. For instance, Odri et al. state the following on page 5: In conclusion, the presence of metastasis during osteosarcoma development is a predictor of poor prognosis. Metastatic diseases are heterogeneous, and the timing, the number, the size, and, probably, other factors also affect patients’ outcomes. Only patients with full surgical resection of all macro metastasis can survive. However, the presence of micro metastatic foci may be frequent and very early events in osteosarcoma progression. Such cases cannot be treated by surgery and may persist after treatment because they contain refractory tumor cells that are resistant to chemotherapy. Therefore, at least in the interest of treating a larger subset of the SOX2 expression-linked cancer population, a skilled artisan would have been motivated to employ the instantly claimed methods. (2 of 2) Claims 83, 117, 119, 123, 135 and 139 are rejected under 35 U.S.C. § 103 as being unpatentable over Liang et al. (Cancer Letters, 2019, 454:108-119) in view of Tang et al. (Cancer Treat Rev, 2017, 59:33-45) and Wan et al. (Oncologist, 2007, 12(8): 1007-1018). Determining the scope and contents of the prior art (See MPEP § 2141.01) Liang et al. teach “that combined 4SC-202 (a novel selective class I HDAC inhibitor) and INK128 (a selective mTORC1/C2 inhibitor) treatment exhibited synergistic effects on inhibiting cell growth, sphere-forming ability, subcutaneous tumor formation and ALDH1+ cancer stem cells (CSCs) in OSCC [i.e., oral squamous cell carcinoma].” See e.g., page 108. Ascertainment of the differences between the prior art and the claims (See MPEP § 2141.02) Regarding instant claims 83 and 135, Liang et al. does not teach the mTOR inhibitor rapamycin and, therefore, does not teach the instantly claimed rapamycin/domatinostat combination. However, Tang et al. teach histone deacetylase (HDAC) inhibitors as “a promising treatment agent for patients with sarcomas.” See e.g., page 42. In addition, Wan et al. teach “the antitumor activity of mTOR inhibitors in subsets of patients with sarcoma.” See e.g., page 1014. For example, Wan et al. disclose Figure 3 on page 1014 which “shows an example of an osteosarcoma patient with...tumor shrinkage” after five days of treatment with a mTOR inhibitor (i.e., AP23573, a rapamycin derivative). Wan et al. also teach that “rapamycin and its analogues inhibit cell growth in a wide variety of human cancer cell lines derived from... [inter alia] osteosarcoma. See e.g., page 1011. Regarding instant claims 117, 119, 123 and 139, Liang et al. does not teach the instantly claimed dosages with respect to domatinostat and rapamycin. Liang et al. does, however, teach mice treated with 4SC-202 (i.e., domatinostat) by oral gavage daily at a dosage of 100 mg/kg. See e.g., page 112. In addition, Tang et al. teach a 1-5 mg daily dosage of sirolimus (i.e., rapamycin). See e.g., page 41. Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) Regarding instant claims 83 and 135, it would, therefore, have been obvious to a person of ordinary skill in the art to arrive at the instantly claimed domatinostat/rapamycin combination based on the combined teachings of the prior art. Considering that Liang et al. teach domatinostat and also “the concomitant inhibition of class I HDAC and mTORC1/C2 [which] synergistically blocks the initiation of OSCC and overcomes chemoresistance by downregulating SOX2 expression” (see e.g., page 117), it would have been obvious for a person of ordinary skill in the art to substitute the mTOR inhibitor (i.e., INK128) taught by Liang et al. with another mTOR inhibitor. In fact, with respect to sarcoma treatment, Tang et al. teach that “combination therapy with other therapeutics including chemotherapy drugs and small-molecular inhibitors such as... sirolimus [i.e., rapamycin] ... seem more promising than [HDAC inhibitors] as monotherapy.” See e.g., page 42. Wan et al. also teach “the effect of rapamycin and its analogues on antiangiogenesis is important for inhibition of both primary and metastatic tumor growth.” See e.g., page 1012. Therefore, with respect to the HDAC inhibitor/mTOR inhibitor combination taught by Liang et al., a person of ordinary skill in the art would reasonably expect that substituting INK128 with another mTOR inhibitor, such as rapamycin, would yield predictable results. MPEP § 2143(I) states: The rationale to support a conclusion that the claim would have been obvious is that the substitution of one known element for another yields predictable results to one of ordinary skill in the art. Therefore, at least in the interest of “improv[ing] the efficacies of [HDAC inhibitors] in future human sarcoma trials to reverse drug resistance” (see e.g., page 42 of Tang et al.), a person of ordinary skill in the art would have been motivated to administer a domatinostat/rapamycin combination to a subject in need either as an initial treatment or a post-treatment strategy (i.e., to “reverse drug resistance”). Regarding instant claims 117, 119, 123 and 139, it would, therefore, have been obvious for a person of ordinary skill in the art to arrive at the instantly claimed dosages for each of domatinostat and rapamycin based on the combined teachings of the prior art. The optimization of result-effective variables, i.e., variables that achieve a recognized result, such as dosages, are considered to be within the ability of the skilled artisan. “It is a settled principle of law that a mere carrying forward of an original patented conception involving only change of form, proportions, or degree, or the substitution of equivalents doing the same thing as the original invention, by substantially the same means, is not such an invention as will sustain a patent, even though the changes of the kind may produce better results than prior inventions.” In re Williams, 36 F.2d 436, 438 (CCPA 1929). Therefore, a skilled artisan would have been motivated to optimize the prior art dosages as part of a routine optimization process. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID SHIM whose telephone number is (571)270-1205. The examiner can normally be reached Monday - Friday, 9 AM - 5 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, RENEE CLAYTOR can be reached at (571)272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D.M.S./Examiner, Art Unit 1626 /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 16, 2024
Application Filed
Jan 07, 2026
Response after Non-Final Action
Oct 27, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758527
ANTIBACTERIAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS
2y 1m to grant Granted Oct 13, 2026
Patent 12746238
SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9
2y 6m to grant Granted Sep 29, 2026
Patent 12698284
SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE
2y 11m to grant Granted Aug 04, 2026
Patent 12686676
COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION
2y 7m to grant Granted Jul 21, 2026
Patent 12673056
ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD
3y 7m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
99%
With Interview (+57.8%)
Low
PTA Risk
Based on 101 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month